Pipeline Overview

Iconic Therapeutics is pioneering a new class of therapeutics that target diseases in which tissue factor (TF) is overexpressed. Our pipeline includes two programs based on our TF platform.

ICON-1, our lead program, is in Phase 2 development in wet age-related macular degeneration (AMD). Our goal is to administer this investigational medicine in combination with standard-of-care anti-VEGF therapy to prevent disease progression as well as treat symptoms.

ICON-2 is in preclinical development for solid tumors. Preclinical data in multiple tumors have shown encouraging signals. Based on these findings, we plan to advance ICON-2 into IND-enabling studies in 2018.